Therapeutic strategies against BK polyomavirus infection in kidney transplant recipients: Systematic review and meta-analysis

Transpl Immunol. 2023 Dec:81:101953. doi: 10.1016/j.trim.2023.101953. Epub 2023 Nov 4.

Abstract

Background: The selection of antiviral therapy for BK polyomavirus (BKPyV) infection has been extensively debated. Our study aimed to assess the efficacy and safety of various treatments for BKPyV infection.

Methods: We searched PubMed, EMBASE, and Web of Science databases for relevant studies regarding drug treatments for BKPyV viremia/DNAemia published between January 1, 1970 and September 30, 2022. Two independent authors screened the published studies, extracted pertinent data, and evaluated their methodological quality. A meta-analysis was performed using the RevMan software version 4.2.2.

Results: A total of 33 published studies involving 986 patients were included in the meta-analysis. Overall, therapeutic interventions comprised immunosuppression reduction alone or in combination with leflunomide, intravenous immunoglobulin (IVIG), cidofovir, or mTOR inhibitor (mTORi) therapy. The meta-analysis revealed that the efficacy of immunosuppression reduction alone for serum BKPyV clearance was 68% (95% confidence interval [CI]: 0.58-0.77; I2 = 78%). Moreover, the efficacy of immunosuppression reduction in combination with leflunomide, cidofovir, IVIG, or mTORi therapy for serum BKPyV clearance was 61% (95% CI: 0.47-0.74; I2 = 83%), 71% (95% CI: 0.63-0.78; I2 = 0), 87% (95% CI: 0.82-0.93; I2 = 45%), and 80% (95% CI: 0.59-1.00; I2 = 58%), respectively. Compared to immunosuppression reduction alone, immunosuppression reduction combined with IVIG therapy offered a statistically significant benefit in serum BKPyV clearance (P < 0.01) with minimal adverse reactions, whereas other adjunctive drug treatments did not demonstrate considerable effects.

Conclusions: Reducing immunosuppression remains the primary approach for treating BKPyV infection. Although the combination treatment with IVIG proved to be most effective, other agents might offer varied antiviral advantages of high heterogeneity, which should be substantiated in future long-term randomized controlled trials.

Keywords: BK polyomavirus; Cidofovir; Immunosuppressants; Intravenous immunoglobulin; Kidney transplantation; mTOR inhibitor.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • BK Virus*
  • Cidofovir / pharmacology
  • Cidofovir / therapeutic use
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Kidney Transplantation* / adverse effects
  • Leflunomide / pharmacology
  • Leflunomide / therapeutic use
  • Polyomavirus Infections* / drug therapy
  • Transplant Recipients
  • Tumor Virus Infections* / drug therapy

Substances

  • Cidofovir
  • Leflunomide
  • Immunoglobulins, Intravenous